<code id='389F418C49'></code><style id='389F418C49'></style>
    • <acronym id='389F418C49'></acronym>
      <center id='389F418C49'><center id='389F418C49'><tfoot id='389F418C49'></tfoot></center><abbr id='389F418C49'><dir id='389F418C49'><tfoot id='389F418C49'></tfoot><noframes id='389F418C49'>

    • <optgroup id='389F418C49'><strike id='389F418C49'><sup id='389F418C49'></sup></strike><code id='389F418C49'></code></optgroup>
        1. <b id='389F418C49'><label id='389F418C49'><select id='389F418C49'><dt id='389F418C49'><span id='389F418C49'></span></dt></select></label></b><u id='389F418C49'></u>
          <i id='389F418C49'><strike id='389F418C49'><tt id='389F418C49'><pre id='389F418C49'></pre></tt></strike></i>

          Home / hotspot / focus

          focus


          focus

          author:hotspot    Page View:7164
          Boston Scientific headquarters -- Health coverage from STAT
          Boston Scientific is growing its urology portfolio with the Axonics acquisition. Steven Senne/AP

          Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion.

          It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. Boston Scientific said it expects to close the deal in the first half of this year. Axonics’ stock increased by 20% in light of the news; Boston Scientific’s dropped slightly.

          advertisement

          Boston Scientific has acquired companies across all medtech sectors in the past year. The device maker bought Apollo Endosurgery, a company selling surgical tools to combat obesity, for $615 million in 2023. In September of 2023, Boston Scientific bought pain relief company Relievant for $850 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In